Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 13Neoplasm Metastasis 10Neoplasms 8Lung Neoplasms 6Colorectal Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Melanoma 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreas Adenocarcinoma 1

Interventions

Gemcitabine 3Leucovorin 2Fluorouracil 2pamrevlumab 1irinotecan sucrosofate 1folfirinox 1Taxes 1Oxaliplatin 1Irinotecan 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Cancer Non-resectable × Taxes × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡